Minnesota is currently home to 2107 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform
NCT06344416
Recruiting
Primary Objective: • To assess the persistence of ReX technology platform use, measured by the percentage (%) of participants who used ReX: 1) throughout the study period and 2) before the treatment discontinuation. Secondary Objective: • To evaluate the impact of the ReX technology platform on ribo treatment duration and ribo dose taking adherence as compared to control group.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Allina, Minneapolis, Minnesota
Conditions: Any Solid Oral Medication
Register for Updates
Bladder Bank (a Prospective Banking Study)
NCT06109857
Recruiting
This study collects blood and urine samples from patients with bladder cancer to support the development of tests for early detection of bladder cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Bladder Carcinoma
Register for Updates
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
NCT06079398
Recruiting
This trial is a Phase 2, multicenter, double-blind, randomized (ratio 2:1 TransCon CNP vs. placebo), placebo-controlled trial, designed to evaluate the safety, tolerability, and efficacy of 100 μg CNP/kg of Navepegritide (TransCon CNP) administered SC once-weekly for 52 weeks in infants with genetically verified heterozygous ACH, aged 0 to \< 2 years at the time of randomization.
Gender:
ALL
Ages:
Between 0 years and 2 years
Trial Updated:
03/10/2025
Locations: Ascendis Investigational Site, Saint Paul, Minnesota
Conditions: Achondroplasia
Register for Updates
Helix Research Network
NCT06057181
Recruiting
The Helix Research Network ("HRN") is a network of academic, public, and/or private healthcare organizations that are committed to advancing medical research and improving human health through large-scale genomics research and acceleration of the integration of genomic and other omics data into clinical care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: HealthPartners (myGenetics), Bloomington, Minnesota
Conditions: Genetic Predisposition to Disease, Genetics Disease
Register for Updates
A Study of Contralateral Limb Block
NCT06045936
Recruiting
This research is being done to determine if an anesthetic like Lidocaine, may be effective when injected around the sciatic nerve of the intact limb in patients with limb loss pain on the contralateral side.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Mayo Clinic Health System - Mankato, Mankato, Minnesota
Conditions: Limb Pain, Phantom
Register for Updates
iTBS rTMS in Mild Cognitive Impairment
NCT05327257
Recruiting
The purposes of this research are to test whether it is feasible to administer a treatment protocol called intermittent theta burst stimulation (iTBS) repetitive transcranial magnetic stimulation (rTMS) in adults with mild cognitive impairment (MCI), and to test whether iTBS rTMS treatments can improve memory in mild cognitive impairment (MCI).
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
03/10/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Mild Cognitive Impairment
Register for Updates
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
NCT05582993
Recruiting
The main aim of the study is to evaluate the effectiveness of prophylaxis with vonicog alfa (recombinant von Willebrand factor \[rVWF\]) in children. This study will enroll those participants who have been previously treated with VWF product or with a plasma-derived VWF (pdVWF) product. In this study, participants will be treated with vonicog alfa (rVWF) for 12 months. During the study, participants will visit the study clinic 5 times after treatment initiation.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
03/07/2025
Locations: Children's Health Care d/b/a Children's Minnesota, Minneapolis, Minnesota
Conditions: Von Willebrand Disease (VWD)
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
NCT05436834
Recruiting
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to \<6 years, when administered as a primary series in SARS-CoV-2 vaccine-naïve participants (Part 1) and a single booster dose (BD) given to participants who previously received 2 doses of the mRNA-1273 vaccine as a primary series (Part 2); and will evaluate the safety and immunogenicity of t... Read More
Gender:
ALL
Ages:
Between 6 months and 5 years
Trial Updated:
03/07/2025
Locations: Clinical Research Institute, Minneapolis, Minnesota
Conditions: SARS-CoV-2
Register for Updates
Backtracking Leukemia-Typical Somatic Mutations in Cord Blood
NCT05014165
Recruiting
A comprehensive mechanistic and epidemiological study to obtain banked cord blood samples from consecutive childhood leukemia patients enrolled in the COG Project:EveryChild (APEC14B1) study. Will attempt to backtrack the initiating genomic alteration identified in the matched diagnostic leukemia sample and molecularly characterize pre-leukemic cells. The ultimate goal of this research is to pinpoint the cell of origin of leukemogenic alterations formed in utero, elucidating the etiology of thes... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
03/07/2025
Locations: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Register for Updates
Allo HSCT for High Risk Hemoglobinopathies
NCT06872333
Recruiting
A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.
Gender:
ALL
Ages:
55 years and below
Trial Updated:
03/06/2025
Locations: Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Graft Failure, Sickle Cell Disease, Hemoglobinopathies
Register for Updates
Methadone Versus Intrathecal Hydromorphone for Postoperative Pain Relief in Gynecologic Cancer Undergoing Surgery
NCT06525740
Recruiting
This phase IV trial compares methadone versus hydromorphone given in the fluid-filled space between the thin layers of tissue that cover the brain and spinal cord (intrathecal) for postoperative pain relief in patients with gynecologic cancer undergo surgery. Methadone binds to opioid receptors in the central nervous system and is a long-acting opioid pain medication. Intrathecal hydromorphone works by changing the way the brain and nervous system respond to pain and is similar to an epidural. T... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
03/06/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Malignant Female Reproductive System Neoplasm
Register for Updates
Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
NCT06279572
Recruiting
This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Acute Myeloid Leukemia
Register for Updates